药物外排泵与生物被膜在微生物耐药机制中的相关性研究进展

生物被膜是介导微生物耐药与多重耐药的一大热点机制,涉及微生物的生长代谢、耐药基因等基因表型改变、群体感应系统的调控及药物外排泵等多重因素。耐药基因、药物外排泵与生物被膜在微生物耐药机制中,具有复杂而密切的相互影响。分别从生物被膜对药物外排泵、耐药基因的影响,药物外排泵对生物被膜的影响,以及药物外排泵和微生物生物被膜共同的调节因素,对近年来的相关研究进展作一综述。     

革兰氏阴性菌多药外排泵MacAB-TolC的功能与结构

病原菌日益增长的多药耐药性已成为人类健康和生命的主要威胁之一。多药外排泵介导的药物主动外排是细菌产生耐药性的主要原因之一，给感染性疾病的防治带来了极大挑战。深入研究多药外排泵，了解其作用机制，揭示药物结合位点，可以为临床抗感染治疗提供新思路。在革兰氏阴性菌中，一些多药外排泵形成跨越细菌胞外被膜的三联复合物。MacAB-TolC是普遍存在于革兰氏阴性菌中的ABC家族三联外排泵，在近些年逐渐被关注。本文综述了关于MacAB-TolC外排泵的功能与结构研究以及相应抑制剂研发方面的进展。MacAB-TolC外排泵的底物种类多样，包含抗生素、毒力因子以及代谢产物。本文据此将MacAB-TolC外排泵的功能归纳为3类：耐药功能、病理功能和生理功能，并对相应功能分别进行了阐述。在结构研究方面，本文总结了MacAB-TolC外排泵单个组分的晶体结构和组装完全的MacAB-TolC三联外排泵的冷冻电镜单颗粒结构，并对结构数据所揭示的MacAB-TolC外排泵发挥功能的机制进行了论述。最后，本文介绍了MacAB-TolC外排泵抑制剂的最新研究进展，指出解析MacAB-TolC的原位结构，以及MacB结合底...     

大肠杆菌耐药过程中的主动外排机制

主动外排系统能将多种药物多大肠杆菌细胞内泵出细胞外,从而生产耐药性。在大肠杆菌耐药株和敏感株均有该系统存在,但在耐药株中,其功能增强。     

重组细菌多药外排泵AcrAB-TolC的转运功能和动态组装

【背景】多药外排泵多以膜蛋白复合体形式存在,是导致细菌耐药性的重要原因。外排泵的转运功能和组装过程对于细菌耐药性和药物研发具有重要意义。【目的】以多药外排泵耐药结节细胞分化家族(resistance-nodulation-division family, RND)的重要成员AcrAB-TolC复合体为对象,研究其转运活性和体外组装特性。【方法】基于大肠杆菌AcrAB-TolC复合体基因序列,分别构建含有acrA、acrB、tolC基因的重组质粒,表达和纯化复合体各亚基,利用荧光光谱、等温滴定量热法(isothermal titration calorimetry,ITC)等技术分析复合体及亚基的转运功能、亚基与底物的相互作用,以及亚基间的相互作用和动态装配。【结果】实现了AcrAB-TolC复合体各组分的表达和纯化(纯度>98%),证实表达有各组分的活细胞提高了对于溴化乙锭(ethidium bromide,EB)的转运活性,并发现群体感应效应信号分子N-hexanoyl-L-homoserine lactone (C6-HSL)能够抑制AcrB、TolC对于EB的转运活性。ITC结果进一步证实了C6-HSL与AcrB、TolC的相互作用。ITC结果还显示AcrA分别与AcrB、TolC之间存在明显的相互作用,而AcrB与TolC之间无明显的相互作用。在体外装配实验中观测到AcrAB-TolC亚基的单分子荧光强度随时间增加,证实了复合体亚基在膜上的动态组装过程。【结论】实现了AcrAB-TolC外排泵及亚基的表达和纯化,证实了AcrAB-TolC对底物的转运活性及与底物的相互作用,观察到AcrAB-TolC的动态组装过程。以上结果为研究多药外排泵导致的细菌耐药性及抗菌策略具有重要意义。     

《细胞研究》:抗生素耐药性研究取得进展

<正>细菌的药物抗性是当今全球面临的主要公共健康威胁之一。抗药性相关的机制研究及对策已成为世界卫生组织和各国政府共同关注的问题。日前,中科院生物物理所张凯、赵永芳课题组合作,在抗生素耐药性研究领域取得进展,相关成果发布于《细胞研究》。细菌有多种形式的抗药机制,最普遍的一种机制是利用细胞膜上的多个药物外排泵,将抗生素外排出细胞。大肠杆菌MFS家族的多药物外排蛋白Mdf A是抗药机制研究中的范例,对该蛋白结构的解析有助于深入认识细菌的药物外排机制。张凯课题组成功解析了Mdf A-氯霉素以及     

华癸根瘤菌7653R中一个RND型药物外排泵的功能表型及调控鉴定

【目的】研究华癸根瘤菌7653R中MCHK_0866和MCHK_0867编码的RND家族外排泵的功能表型。【方法】对外排泵编码基因及候选调控基因在基因组上的结构进行分析。采用测定OD_(600)观察菌株生长曲线的变化。通过测定最低抑菌浓度检测菌株的药物敏感性,RT-PCR检测目的基因经特定物质处理后表达量的变化。通过细菌单杂交系统初步检测外排泵的转录调控。【结果】MCHK_0866和MCHK_0867所编码蛋白共同组成一个RND家族射流泵。缺失该外排泵后,细菌生长曲线在稳定期OD_(600)数值降低,对萘啶酸、四环素和SDS的敏感性发生变化,萘啶酸处理细菌后2个基因的表达量增加。同时,下游属于Tet R转录因子家族的基因MCHK_0869表达产物作用于MCHK_0867的启动子区域。【结论】该外排泵与萘啶酸的运输有关,缺失后自身生长受到影响,表达受到下游转录因子的调控。     

鲍曼不动杆菌耐药程度与其主动外排泵蛋白的相关性研究

目的:探讨鲍曼不动杆菌耐药程度与其主动外排泵蛋白的相关性。方法:首先用纸片扩散法检测64株临床鲍曼不动杆菌对8种抗菌药物的敏感性;将其分为A组(0～2种抗生素耐药)、B组(对3～5种抗生素耐药)和C组(对6～8种抗生素耐药);检测64株临床鲍曼不动杆菌对罗丹明6G的外排情况,筛选出罗丹明6G外排明显增加的菌株;并用逆转录-聚合酶链反应(RT-PCR)方法检测主动外排泵基因AdeABC的表达水平。结果:64株鲍曼不动杆菌中有4株对0～2种抗生素耐药(A组),对3～5种抗生素耐药的有33株(B组),对6～8种抗生素耐药的有27株(C组);多重耐药组鲍曼不动杆菌罗丹6G外排明显增高,外排程度A组相似文献   

AdeABC外排泵在鲍曼不动杆菌对亚胺培南耐药中的作用研究

目的探讨AdeABC外排泵在鲍曼不动杆菌对亚胺培南耐药中的作用。方法收集亚胺培南耐药鲍曼不动杆菌(imipenem resistant acinetobacter baumannii, IRAB)和亚胺培南敏感株(imipenem-sensitive Acinetobacter baumannii, ISAB)各30株。用琼脂稀释法检测其对抗菌药物的最低抑菌浓度(minimum inhibition concentrations, MIC),加入外排泵抑制剂PAβN检测外排泵表型;用聚合酶链反应(polymerase chain reaction, PCR)、逆转录实时荧光定量PCR(Real time fluorescence quantitative PCR, RT-qPCR)分别检测adeB基因阳性率及相对表达量。DNA重组技术将adeABC-RS基因转入adeB阴性的ISAB,测定MIC变化。结果 IRAB对多黏菌素B敏感,对头孢哌酮/舒巴坦耐药率46.7%,对其他抗菌药物耐药率高于ISAB,差异有统计学意义(P0.05)。70.0%IRAB外排泵表型阳性,而ISAB全阴性。基因检测显示IRAB的adeB阳性率和相对表达量均高于ISAB,差异有统计学意义(P0.05)。DNA重组证实,将adeABC-RS基因导入ISAB中,亚胺培南MIC提高64～128倍。结论 IRAB往往表现为多重耐药,AdeABC外排泵是导致其耐药的重要原因。     

西瓜食酸菌RND蛋白家族外排转运体cusB基因抗铜功能研究

【目的】研究RND外排泵中cus B基因突变对西瓜食酸菌抗铜性的影响。【方法】采用Tn5转座子随机插入基因组制备筛选得到突变体,通过双亲杂交的方法构建功能互补菌株,并从西瓜食酸菌抗铜性、胞外纤维素酶和胞外蛋白酶分泌、胞外多糖产生、生物膜形成、致病性及过敏性反应等方面阐明RND外排泵中MFP蛋白亚基对西瓜食酸菌的影响。【结果】突变体Δcus B在含有1.25 mmol/L或2.5 mmol/L Cu SO4的KMB平板上不能生长,cus B基因的突变导致西瓜食酸菌的胞外多糖分泌和生物膜形成与野生型有差异,但不影响胞外纤维素酶、胞外蛋白酶、致病性及过敏性反应。【结论】RND外排泵相关基因cus B的突变会影响西瓜食酸菌的某些生物学特性,并导致病菌对铜十分敏感。研究以RND外排泵转运重金属为导向初步解析了西瓜食酸菌的抗铜机制。     

外排泵抑制剂对阴沟肠杆菌耐药表型影响

目的探讨主动外排泵在临床分离阴沟肠杆菌多重耐药的作用。方法收集、分离及鉴定阴沟肠杆菌,采用琼脂稀释法测定多重耐药泵抑制剂氰氯苯腙(carbonyl cyanldem-chlorophenylhydrazone,CCCP)应用前后,阴沟肠杆菌对头孢他啶、阿米卡星、阿奇霉素、左氧氟沙星和四环素5种抗生素的最小抑菌浓度(MIC)的变化。结果以上述5种抗生素为底物8,3株阴沟肠杆菌中,分别有303、61、9、32和28株在10μg/mL CCCP条件下MIC值降低4倍或4倍以上,其中有19株同时对3种及以上抗生素有明显外排作用。外排泵存在于耐药株和非耐药株中,但对耐药株的影响较大。结论主动外排系统广泛存在于临床分离阴沟肠杆菌中,是引起阴沟肠杆菌多重耐药的重要机制。外排泵抑制剂CCCP可增加阴沟肠杆菌对抗菌药物的敏感性。     

Continuous in situ electrochemical monitoring of doxorubicin efflux from sensitive and drug-resistant cancer cells.

One of the least well understood problems in cancer chemotherapy is the cross-resistance of certain tumor cells to a series of chemically unrelated drugs. Multidrug resistance (MDR) can be attributed to several different biophysical processes, among them increased drug efflux. This has been found to correlate with overexpression of the cell surface 170-kDa P-glycoprotein that actively excludes cytotoxic drugs against their concentration gradient. To better understand MDR, experimental methods are needed to study drug efflux from cancer cells. Continuous measurement of efflux of nonfluorescent drugs on the same cell culture in situ, or assessing efflux from a few cells or even a single cell, is beyond the capabilities of existing technologies. In this work, a carbon fiber (CF) microelectrode is used to monitor efflux of doxorubicin from a monolayer of two cell lines: an auxotrophic mutant of Chinese hamster ovary cells, AUXB1, and its MDR subline, CHRC5. Because doxorubicin is both fluorescent and electroactive, the results could be validated against existing data obtained optically and with other techniques on the same cell lines, with good agreement found. The electrochemical detection, however, is capable of in situ monitoring with high temporal resolution and is suitable for single-cell studies.     

Multiple physiological functions for multidrug transporter P-glycoprotein?

Multidrug resistance mediated by the drug-efflux protein P-glycoprotein (P-gp) is one mechanism that tumor cells use to escape death induced by chemotherapeutic drugs. Although it is irrefutable that P-gp can efflux xenobiotics out of cells, biological regulatory functions for P-gp in multicellular organisms have yet to be established firmly. Recent observations have challenged the notion that P-gp has evolved merely to efflux xenotoxins out of healthy cells and raised the possibility that P-gp and related transporter molecules might play a fundamental role in regulating cell differentiation, proliferation and survival.     

Multidrug resistance: a role for cholesterol efflux pathways?

Multidrug resistance (MDR) severely impairs the efficacy of cancer chemotherapy. Several protein transporters that mediate drug export have been identified, but additional adaptations appear to be necessary for full-fledged drug resistance. The cell surface density of caveolae and the expression of the caveolar coat protein caveolin are dramatically increased in MDR cancer cells. Acquisition of MDR might thus be accompanied by upregulation of caveolin-dependent cholesterol efflux pathways, raising the possibility that these same pathways are utilized for delivering drugs from intracellular compartments to the plasma membrane, where drugs can be extruded from the cells by drug efflux ATPases. The upregulation of caveolin mandates a phenotypic change of MDR cells in terms of their cholesterol homeostasis and is accompanied by loss of important features of the transformed phenotype of MDR cancer cells.     

Control of the AcrAB multidrug efflux pump by quorum-sensing regulator SdiA

SdiA is an Escherichia coli protein that regulates cell division in a cell density-dependent, or quorum-sensing, manner. We report that SdiA also controls multidrug resistance by positively regulating the multidrug resistance pump AcrAB. Overproduction of SdiA confers multidrug resistance and increased levels of AcrAB. Conversely, sdiA null mutants are hypersensitive to drugs and have decreased levels of AcrB protein. Our findings provide a link between quorum sensing and multidrug efflux. Combined with previously published reports, our data support a model in which a role of drug efflux pumps is to mediate cell-cell communication in response to cell density. Xenobiotics expelled by pumps may resemble the communication molecules that they normally efflux.     

Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein

Installation of a C2-aminopropyl side chain to the 2,4-diaryl-2,5-dihydropyrrole series of kinesin spindle protein (KSP) inhibitors results in potent, water soluble compounds, but the aminopropyl group induces susceptibility to cellular efflux by P-glycoprotein (Pgp). We show that by carefully modulating the basicity of the amino group by beta-fluorination, this series of inhibitors maintains potency against KSP and has greatly improved efficacy in a Pgp-overexpressing cell line. The discovery that cellular efflux by Pgp can be overcome by carefully modulating the basicity of an amine may be of general use to medicinal chemists attempting to transform leading compounds into cancer cell- or CNS-penetrant drugs.     

Fast kinetic analysis of drug transport in multidrug resistant cells using a pulsed quench-flow apparatus

One major feature of multidrug resistance is the reduced cellular level of drugs maintained by MDR cells. Although there is now strong evidence that drugs are actively pumped out of MDR cells, transport experiments have indicated decreased initial rates of influx at the earliest times at which measurements could be made. We have used a pulsed quench-flow apparatus to study transport characteristics of colchicine resistant MDR cells on a very fast time scale. A rapid association of daunomycin with drug sensitive cells occurred within 0.11 sec. This association is virtually absent in MDR cells. In efflux experiments performed on the same rapid time scale, greater than 50% of daunomycin efflux occurred within 0.1 sec. No substantial efflux from B1, drug sensitive cells was observed. On the other hand, vinblastine accumulation by both cell types was similar for approx. 10 seconds. Thus, kinetically, not all drugs are handled in a similar fashion by MDR cells. The pulsed quench-flow apparatus was useful in making fast time measurements of drug influx and efflux and in demonstrating the differences between drug recognition patterns by MDR cells.     

Proton-dependent multidrug efflux systems.

Multidrug efflux systems display the ability to transport a variety of structurally unrelated drugs from a cell and consequently are capable of conferring resistance to a diverse range of chemotherapeutic agents. This review examines multidrug efflux systems which use the proton motive force to drive drug transport. These proteins are likely to operate as multidrug/proton antiporters and have been identified in both prokaryotes and eukaryotes. Such proton-dependent multidrug efflux proteins belong to three distinct families or superfamilies of transport proteins: the major facilitator superfamily (MFS), the small multidrug resistance (SMR) family, and the resistance/ nodulation/cell division (RND) family. The MFS consists of symporters, antiporters, and uniporters with either 12 or 14 transmembrane-spanning segments (TMS), and we show that within the MFS, three separate families include various multidrug/proton antiport proteins. The SMR family consists of proteins with four TMS, and the multidrug efflux proteins within this family are the smallest known secondary transporters. The RND family consists of 12-TMS transport proteins and includes a number of multidrug efflux proteins with particularly broad substrate specificity. In gram-negative bacteria, some multidrug efflux systems require two auxiliary constituents, which might enable drug transport to occur across both membranes of the cell envelope. These auxiliary constituents belong to the membrane fusion protein and the outer membrane factor families, respectively. This review examines in detail each of the characterized proton-linked multidrug efflux systems. The molecular basis of the broad substrate specificity of these transporters is discussed. The surprisingly wide distribution of multidrug efflux systems and their multiplicity in single organisms, with Escherichia coli, for instance, possessing at least nine proton-dependent multidrug efflux systems with overlapping specificities, is examined. We also discuss whether the normal physiological role of the multidrug efflux systems is to protect the cell from toxic compounds or whether they fulfil primary functions unrelated to drug resistance and only efflux multiple drugs fortuitously or opportunistically.     

Beta-lactam antibiotic resistance: a current structural perspective

Bacterial resistance to beta-lactam antibiotics can be achieved by any of three strategies: the production of beta-lactam-hydrolyzing beta-lactamase enzymes, the utilization of beta-lactam-insensitive cell wall transpeptidases, and the active expulsion of beta-lactam molecules from Gram-negative cells by way of efflux pumps. In recent years, structural biology has contributed significantly to the understanding of these processes and should prove invaluable in the design of drugs to combat beta-lactam resistance in the future.     

Role of mycobacterial efflux transporters in drug resistance: an unresolved question

Two mechanisms are thought to be involved in the natural drug resistance of mycobacteria: the mycobacterial cell wall permeability barrier and active multidrug efflux pumps. Genes encoding drug efflux transporters have been isolated from several mycobacterial species. These proteins transport tetracycline, fluoroquinolones, aminoglycosides and other compounds. Recent reports have suggested that efflux pumps may also be involved in transporting isoniazid, one of the main drugs used to treat tuberculosis. This review highlights recent advances in our understanding of efflux-mediated drug resistance in mycobacteria, including the distribution of efflux systems in these organisms, their substrate profiles and their contribution to drug resistance. The balance between the drug transport into the cell and drug efflux is not yet clearly understood, and further studies are required in mycobacteria.     

The protein synthesis inhibitors mycalamides A and E have limited susceptibility toward the drug efflux network

The mycalamides belong to a family of protein synthesis inhibitors noted for antifungal, antitumour, antiviral, immunosuppressive, and nematocidal activities. Here we report a systematic analysis of the role of drug efflux pumps in mycalamide resistance and the first isolation of mycalamide E. In human cell lines, neither P-glycoprotein overexpression nor the use of efflux pump inhibitors significantly modulated mycalamide A toxicity in the systems tested. In Saccharomyces cerevisiae, it appears that mycalamide A is subject to efflux by the principle mediator of xenobiotic efflux, Pdr5p along with the major facilitator superfamily pump Tpo1p. Mycalamide E showed a similar efflux profile. These results suggest that future drugs based on the mycalamides are likely to be valuable in situations where efflux pump-based resistance leads to failure of other chemotherapeutic approaches, although efflux may be a mediator of resistance in antifungal applications.